MA43530A - Modulateurs de transport nucléaire et leurs utilisations - Google Patents
Modulateurs de transport nucléaire et leurs utilisationsInfo
- Publication number
- MA43530A MA43530A MA043530A MA43530A MA43530A MA 43530 A MA43530 A MA 43530A MA 043530 A MA043530 A MA 043530A MA 43530 A MA43530 A MA 43530A MA 43530 A MA43530 A MA 43530A
- Authority
- MA
- Morocco
- Prior art keywords
- nuclear transport
- transport modulators
- modulators
- nuclear
- transport
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273964P | 2015-12-31 | 2015-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43530A true MA43530A (fr) | 2018-11-07 |
Family
ID=57799959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043530A MA43530A (fr) | 2015-12-31 | 2016-12-30 | Modulateurs de transport nucléaire et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10709706B2 (fr) |
| EP (1) | EP3397634A1 (fr) |
| MA (1) | MA43530A (fr) |
| WO (1) | WO2017117535A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087342A1 (es) | 2011-07-29 | 2014-03-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y sus usos |
| ME03795B (fr) | 2012-05-09 | 2021-04-20 | Biogen Ma Inc | Modulateurs de transport nucléaire et leurs utilisations |
| WO2014144772A1 (fr) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1 |
| US9738624B2 (en) | 2013-06-21 | 2017-08-22 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| AU2015301484B2 (en) | 2014-08-15 | 2020-02-20 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| MA43529A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| MA43530A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| WO2019232724A1 (fr) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Composés en tant que modulateurs de transport nucléaire et leurs utilisations |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| BR9509760A (pt) | 1994-11-23 | 1998-06-30 | Neurogen Corp | Composto |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| WO1997015567A1 (fr) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants |
| EP0893446B1 (fr) | 1996-04-04 | 2006-10-04 | Shionogi & Co., Ltd. | Composes de cephem et medicaments contenant ces composes |
| EP0913392B1 (fr) | 1996-04-25 | 2003-07-02 | Nissan Chemical Industries, Limited | Derives ethyleniques et agents pesticides |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| ES2257441T3 (es) | 2000-09-29 | 2006-08-01 | Topotarget Uk Limited | Compuestos de acido carbonico que comprenden un enlace amino como inhibidores hdac. |
| US7595343B2 (en) | 2001-09-14 | 2009-09-29 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| EP1556032A1 (fr) | 2002-11-01 | 2005-07-27 | Takeda Pharmaceutical Company Limited | Agent pour la prevention ou le traitement de neuropathie |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| WO2004043925A2 (fr) | 2002-11-08 | 2004-05-27 | Neurogen Corporation | 6-aryl pyridines substituees en 3 |
| CA2512886A1 (fr) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands modulant des recepteurs du type lxr |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| KR20070050475A (ko) | 2004-08-11 | 2007-05-15 | 교린 세이야꾸 가부시키 가이샤 | 신규 환상 아미노 안식향산 유도체 |
| WO2006019020A1 (fr) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | Urées de substitution |
| EP1849465A4 (fr) | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | Agent de controle de la fonction du recepteur gpr34 |
| SI1954684T1 (sl) | 2005-11-15 | 2014-07-31 | Otsuka Pharmaceutical Co., Ltd. | Oksazolna spojina in farmacevtski sestavek |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| CA2643796A1 (fr) | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Derive polycyclique de cinnamide |
| EP2007720B1 (fr) | 2006-04-07 | 2013-12-25 | MethylGene Inc. | Derives de benzamide utilises en tant qu'inhibiteurs de l'histone desacetylase |
| EP2014652B1 (fr) | 2006-04-18 | 2014-08-06 | Nippon Chemiphar Co., Ltd. | Agent d'activation du récepteur activé par les proliférateurs des peroxisomes |
| JP4999923B2 (ja) | 2006-06-13 | 2012-08-15 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物 |
| PL2054411T3 (pl) | 2006-07-27 | 2015-02-27 | Amorepacific Corp | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne |
| AU2007292155B2 (en) | 2006-09-05 | 2012-11-01 | Kyowa Kirin Co., Ltd. | Imidazole derivative |
| EP1942104A1 (fr) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
| EP1939180A1 (fr) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale |
| JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | カルバメート化合物 |
| EP2003118A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2 |
| MX2012000434A (es) | 2009-07-09 | 2012-04-11 | Crescendo Therapeutics Llc | Metodo de sanacion de herida y modulacion de cicatriz. |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| US9303000B2 (en) * | 2011-01-17 | 2016-04-05 | Karyopharm Therapeutics Inc. | Olefin containing nuclear transport modulators and uses thereof |
| AR087342A1 (es) | 2011-07-29 | 2014-03-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y sus usos |
| CA2842364A1 (fr) * | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucleaire et leurs utilisations |
| WO2013020024A2 (fr) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Composés de maléimide et méthodes de traitement |
| ME03795B (fr) | 2012-05-09 | 2021-04-20 | Biogen Ma Inc | Modulateurs de transport nucléaire et leurs utilisations |
| WO2014152263A1 (fr) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations |
| WO2014144772A1 (fr) * | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1 |
| WO2014205393A1 (fr) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US9738624B2 (en) * | 2013-06-21 | 2017-08-22 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2015073908A1 (fr) | 2013-11-15 | 2015-05-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Procédé de sélection d'un schéma de traitement du cancer |
| EP3172214B1 (fr) | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido [2,3-d]pyrimidin -7 (8h)-one utilisés en tant qu'inhibiteurs de cdk et utilisations de ceux-ci |
| AU2015301484B2 (en) | 2014-08-15 | 2020-02-20 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| MA43530A (fr) * | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| MA43529A (fr) * | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| US11034675B2 (en) | 2016-01-08 | 2021-06-15 | Dr. Reddy's Laboratories Limited | Solid forms of Selinexor and process for their preparation |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| US10993943B2 (en) | 2017-01-05 | 2021-05-04 | Watson Laboratories Inc. | Crystalline forms of selinexor and process for their preparation |
-
2016
- 2016-12-30 MA MA043530A patent/MA43530A/fr unknown
- 2016-12-30 EP EP16826684.9A patent/EP3397634A1/fr not_active Withdrawn
- 2016-12-30 US US16/066,572 patent/US10709706B2/en active Active
- 2016-12-30 WO PCT/US2016/069508 patent/WO2017117535A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US10709706B2 (en) | 2020-07-14 |
| EP3397634A1 (fr) | 2018-11-07 |
| US20190160063A1 (en) | 2019-05-30 |
| WO2017117535A1 (fr) | 2017-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| FR24C1023I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA56480A (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
| MA50502A (fr) | Adénovirus et utilisations associées | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA43530A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
| DK3308111T3 (da) | Belastningsføler og belastningsføler-anlæg | |
| DK3177259T3 (da) | Forbindelses- og beholdersystem | |
| MA43205A (fr) | Composés pyy sélectifs et leurs utilisations | |
| MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
| MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations |